TUPS

TUPS (1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea) is a potent, selective small-molecule inhibitor of **soluble epoxide hydrolase (sEH)**, an enzyme responsible for the metabolic conversion of epoxyeicosatrienoic acids (EETs) into dihydroxyeicosatrienoic acids (DHETs). Developed primarily in the laboratory of Bruce Hammock at the University of California, Davis, TUPS is widely utilized as a pharmacological tool to investigate the role of the arachidonic acid cascade in various pathologies. By stabilizing endogenous EETs, TUPS exerts anti-inflammatory, antihypertensive, and analgesic effects in preclinical models. However, research has also indicated that sEH inhibition and the resulting elevation of EETs can promote tumor angiogenesis and lymphangiogenesis, potentially accelerating metastasis in certain cancer models such as melanoma and fibrosarcoma.

Other names

1-(1-methanesulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea1-(1-(methylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea